The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Nivolumab in metastatic nonclear cell renal cell carcinoma: First results of the AcSe prospective study.
 
Laurence Albiges
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Exelixis (Inst); Ipsen (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Novartis (Inst); Peloton therapeutics (Inst); Pfizer (Inst); Roche (Inst)
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD
 
Damien Pouessel
Honoraria - Amgen; Astellas Pharma; Boehringer Ingelheim; Janssen; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Lilly; MSD Oncology; Novartis; Roche; Sanofi
Research Funding - Amgen (Inst); MSD Oncology (Inst); Oncogenex (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Novartis; Sanofi
 
Marie Beylot-Barry
No Relationships to Disclose
 
Guido Bens
Consulting or Advisory Role - Bristol-Myers Squibb
Speakers' Bureau - MSD Oncology
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen-Cilag; MSD Oncology; Novartis
 
Diane Pannier
No Relationships to Disclose
 
Céline Gavoille
No Relationships to Disclose
 
Stephane Oudard
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; IPSEN; Janssen; Merck; MSD; Novartis; Pfizer; Roche/Genentech; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; IPSEN; Janssen; Merck; MSD Oncology; MSD Oncology; Novartis; Pfizer; Roche; Roche; Sanofi
Research Funding - Ipsen; Sanofi
Travel, Accommodations, Expenses - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Merck; MSD Oncology; Novartis; Pfizer; Roche
 
Sylvie Chevret
No Relationships to Disclose
 
Natalie Hoog Labouret
Employment - Amgen (I)
 
Frédéric Legrand
No Relationships to Disclose
 
Clotilde Simon
No Relationships to Disclose
 
Assia Lamrani-Ghaouti
No Relationships to Disclose
 
Bernard Escudier
Honoraria - Bristol-Myers Squibb; EUSA Pharma; Ipsen; Novartis; Oncorena; Pfizer; Roche/Genentech
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; EUSA Pharma; Ipsen; Novartis; Pfizer; Roche/Genentech
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; MSD; Pfizer; Roche/Genentech
 
Aurelien Marabelle
Stock and Other Ownership Interests - PEGASCY
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; Merieux Nutrisciences; Oncovir
Consulting or Advisory Role - AMGEN; AstraZeneca; Bayer; Bioncotech; Boehringer Ingelheim; CERENIS THERAPEUTICS; Eisai; Gritstone Bio; ImCheck therapeutics; Innate Pharma; Lytix Biopharma; Merck Serono; Molecular Partners; MSD; NOVARTIS; OSE Immunotherapeutics; Partner Therapeutics; Pfizer; Pfizer; Pierre Fabre; Redx Pharma; Roche; Sanofi; SERVIER; Sotio; Symphogen
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; MSD; Roche
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); MERUS (Inst); MSD (Inst); Transgene (Inst)
Patents, Royalties, Other Intellectual Property - monoclonal antibodies against CD81 (Stanford University)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; MSD; Roche
Other Relationship - PEGASCY
 
Aude Flechon
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; MSD Oncology; PFIZER; Roche/Genentech; Sanofi/Aventis
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; IPSEN; Janssen-Cilag; MSD Oncology; Pfizer; Roche/Genentech; Sanofi/Aventis